Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma.pdf (278.39 kB)
Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
journal contributionposted on 2021-02-17, 05:17 authored by Hui GanHui Gan
• Optimal use of phase II data may reduce chances of failure in subsequent phase III studies.
• Inappropriate utilization or a lack of phase II data appears to contribute to phase III failure.
• Only 35% of phase III trials in our review transitioned from phase II to III in an optimal manner.
PublisherOxford University Press
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.